- Home
- OSBC vs KURA Comparison
OSBC vs KURA Comparison
Compare OSBC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSBC
- KURA
- Stock Information
- Founded
- OSBC 1981
- KURA 2014
- Country
- OSBC United States
- KURA United States
- Employees
- OSBC N/A
- KURA N/A
- Industry
- OSBC Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSBC Finance
- KURA Health Care
- Exchange
- OSBC Nasdaq
- KURA Nasdaq
- Market Cap
- OSBC 838.3M
- KURA 793.2M
- IPO Year
- OSBC N/A
- KURA N/A
- Fundamental
- Price
- OSBC $18.20
- KURA $7.26
- Analyst Decision
- OSBC Buy
- KURA Strong Buy
- Analyst Count
- OSBC 4
- KURA 11
- Target Price
- OSBC $18.75
- KURA $27.89
- AVG Volume (30 Days)
- OSBC 266.3K
- KURA 1.7M
- Earning Date
- OSBC 01-22-2025
- KURA 02-25-2025
- Dividend Yield
- OSBC 1.32%
- KURA N/A
- EPS Growth
- OSBC N/A
- KURA N/A
- EPS
- OSBC 1.85
- KURA N/A
- Revenue
- OSBC $264,069,000.00
- KURA N/A
- Revenue This Year
- OSBC N/A
- KURA N/A
- Revenue Next Year
- OSBC N/A
- KURA $233.30
- P/E Ratio
- OSBC $9.84
- KURA N/A
- Revenue Growth
- OSBC N/A
- KURA N/A
- 52 Week Low
- OSBC $13.00
- KURA $6.98
- 52 Week High
- OSBC $19.37
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- OSBC 55.44
- KURA 19.21
- Support Level
- OSBC $16.92
- KURA $7.02
- Resistance Level
- OSBC $18.52
- KURA $7.66
- Average True Range (ATR)
- OSBC 0.52
- KURA 0.34
- MACD
- OSBC 0.07
- KURA 0.07
- Stochastic Oscillator
- OSBC 80.00
- KURA 13.76
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company's revenue consists of interest, commission, payments, and other income.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.